Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.
